M&A - Soleus Capital Master Fund, L.P.

Form Type: SCHEDULE 13D/A

Filing Date: 2025-04-11

Corporate Action: Acquisition

Type: Update

Accession Number: 000121390025031218

Filing Summary: This Amendment to Schedule 13D, filed by Soleus Capital Master Fund, L.P., updates the beneficial ownership of shares of common stock of Theratechnologies Inc. The Reporting Persons, including Soleus Capital, LLC, Soleus Capital Group, LLC, and others, confirmed their ownership of 4,801,375 shares, or approximately 10.4% of the outstanding shares as of November 30, 2024. The document mentions a proposal from Future Pak, LLC to acquire all outstanding shares of the Issuer's common stock for a cash consideration of $3.51 to $4.50 per share, which represents a premium of at least 163% over the closing price on April 10, 2025. The Reporting Persons have communicated their belief to the Issuer's Board that engaging with Future Pak is in the best interest of the Issuer's shareholders. They plan to review their investment actively and may increase or decrease their holdings depending on various conditions. The report states that no transactions have been made in the Issuer's stock during the last 60 days, and there are no additional actions planned by the Reporting Persons beyond those discussed within this filing.

Document Link: View Document